EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure

Toru Ikegami, Masashi Tsunematsu, Kenei Furukawa, Shinji Onda, Michinori Matsumoto, Yoshihiro Shirai, Koichiro Haruki

Surgery Today · 2025

DOI: 10.1007/s00595-025-03100-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Surgery Today, 2025. Verfasst von Toru Ikegami und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan. toruikegamiji…. Hauptthemen laut MEDLINE: Liver Transplantation, ABO Blood-Group System, Living Donors, Blood Group Incompatibility. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Kakenhi (Grants-in-Aid for Scientific Research).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of rituximab, an anti-CD20 antibody, has changed the treatment strategies and outcomes for ABO-incompatible living donor liver transplantation (ABOi-LDLT) dramatically. Rituximab targets the CD20-positive B-cells that would differentiate into plasma cells, producing antibodies against A or B antigen-expressing cells and causing microvascular multiple thrombosis and graft necrosis or diffuse bile-duct necrosis. Now, the universal desensitization of the ABOi combination between the donor and recipient is performed by rituximab, and ABOi-LDLT has become the treatment of choice for end-stage liver disease. However, because rituximab takes 1-3 weeks to mediate its effects, complicated strategies are necessary to perform ABOi-LDLT for acute liver failure. For example, high-dose intravenous immunoglobulin (IVIG) or bortezomib may be used to alleviate the elevation of isoagglutinin titers. The diagnosis and treatment of antibody-mediated rejection (AMR) remain challenging. Treatment options include plasma exchange, high-dose IVIG, and bortezomib, but the optimal strategies have not been identified. In this review, we discuss standard ABOi-LDLT for chronic liver disease, ABOi-LDLT for acute liver failure, and the diagnosis and treatment of AMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationABO Blood-Group SystemLiving DonorsBlood Group IncompatibilityLiver Failure, AcuteEnd Stage Liver DiseaseHumansGraft RejectionRituximabImmunoglobulins, IntravenousChronic DiseasePlasma ExchangeBortezomib

Stichwörter der Autor:innen

Blood type incompatibleLiving donor liver transplantationRituximab

Substanzen

ABO Blood-Group SystemRituximabImmunoglobulins, IntravenousBortezomib

Autor:innen und Institutionen

  • Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan. toruikegamijikei@jikei.ac.jp.
  • Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.

Förderung

  • Kakenhi (Grants-in-Aid for Scientific Research)

Zitieren

APA

Ikegami, T., Tsunematsu, M., Furukawa, K., Onda, S., Matsumoto, M., Shirai, Y., & Haruki, K. (2025). Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure. Surgery Today. https://doi.org/10.1007/s00595-025-03100-3

Vancouver

Ikegami T, Tsunematsu M, Furukawa K, Onda S, Matsumoto M, Shirai Y, et al. Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure. Surgery Today. 2025. doi:10.1007/s00595-025-03100-3

BibTeX
@article{Ikegami2025,
  author = {Ikegami, Toru and Tsunematsu, Masashi and Furukawa, Kenei and Onda, Shinji and Matsumoto, Michinori and Shirai, Yoshihiro and Haruki, Koichiro},
  title = {Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure},
  journal = {Surgery Today},
  year = {2025},
  doi = {10.1007/s00595-025-03100-3}
}
Kostenlos starten →